drugset / Trial / NCT03699319
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to treat participants with the combination of CPI-613 (the study drug) with FOLFIRINOX (the standard combination of drugs) to determine if it is safe and effective for participants with localized and unresectable pancreatic cancer. This study is specifically for participants who have a pancreatic cancer that is localized and not considered resectable or removable by a surgeon, without additional treatment.
Timeline
- Start
- 2018-12-07
- Primary completion
- 2024-09-23
- Completion
- 2024-09-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPI-613 | Small molecule | 500 mg/m2 | Intravenous |
| Subject | CPI-613 | Small molecule | 750 mg/m2 | Intravenous |
| Subject | CPI-613 | Small molecule | 1000 mg/m2 | Intravenous |
| Background | 5-flurouracil | Unknown | 2400 mg/m2 | Intravenous |
| Background | Irinotecan | Small molecule | 140 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 65 mg/m2 | Intravenous |